ArticleScientific reports2020
Combination of syringaresinol-di-O-β-D-glucoside and chlorogenic acid shows behavioral pharmacological anxiolytic activity and activation of hippocampal BDNF-TrkB signaling.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 22 citations in OpenAlex.
- Investigating the effects of chlorogenic acid on novel object recognition memory impairment, hyperlocomotion, and prefrontal BDNF expression in a sub-chronic ketamine-induced schizophrenia-like rat model.IBRO neuroscience reports · 2026Article
- Compound Ciwujia Granules Attenuate Stress-Induced Anxiety- and Depression-Like Behaviors via Inhibition of TNF-α-Associated Neuroinflammation in the dmPFC.CNS neuroscience & therapeutics · 2026Article
- Evaluation of the TiaoShenZhiAi Regimen for Patients With Ovarian Cancer Experiencing a Psychoneurological Symptom Cluster: Protocol for a Multicenter, Double-Blind, Randomized Controlled Trial.JMIR research protocols · 2026Article
- Chlorogenic Acid: Characteristics, Neuroprotective Effects, and Potential Mechanisms.Current neuropharmacology · 2026Review
- Anxiolytic Effects ofInternational journal of general medicine · 2026Article
- Exploring the Impact and Mechanisms of Coffee and Its Active Ingredients on Depression, Anxiety, and Sleep Disorders.Nutrients · 2025Review
- Syringaresinol attenuates Tau phosphorylation and ameliorates cognitive dysfunction induced by sevoflurane in aged rats.Journal of neuropathology and experimental neurology · 2024Article
- Black Chokeberry (Current issues in molecular biology · 2024Article
- Article
- Antidepressive Effect of Natural Products and Their Derivatives Targeting BDNF-TrkB in Gut-Brain Axis.International journal of molecular sciences · 2022Review
- Shugan Jieyu Capsule in Post-Stroke Depression Treatment: From Molecules to Systems.Frontiers in pharmacology · 2022Review
- Integrated network pharmacology and hepatic metabolomics to reveal the mechanism ofFrontiers in cell and developmental biology · 2022Article
- Anxiolytic and Antidepressant-Like Effects ofPlants (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mental stress, such as anxiety and conflict, causes physiological changes such as dysregulation of autonomic nervous activity, depression, and gastric ulcers. It also induces glucocorticoid production and changes in hippocampal brain-derived neurotrophic factor (BDNF) levels. We previously reported that Acanthopanax senticosus HARMS (ASH) exhibited anxiolytic activity. Thus, we attempted to identify the anxiolytic constituents of ASH and investigated its influence on hippocampal BDNF protein expression in male Sprague Dawley rats administered chlorogenic acid (CHA), ( +)-syringaresinol-di-O-β-D-glucoside (SYG), or a mixture of both (Mix) for 1 week using the open field test (OFT) and improved elevated beam walking (IEBW) test. As with ASH and the benzodiazepine anxiolytic cloxazolam (CLO), Mix treatment significantly increased locomotor activity in the OFT. CHA and Mix increased the time spent in the open arm in the IEBW test. SYG and Mix treatment inhibited the significant increase in normalized low-frequency power, indicative of sympathetic nervous activity, and significant decrease in normalized high-frequency power, indicative of parasympathetic nervous activity, as observed in the IEBW test. SYG and Mix treatment significantly increased hippocampal BDNF protein expression. The combination of CHA and SYG possibly induces anxiolytic behavior and modulates autonomic regulation, activates hippocampal BDNF signaling as with ASH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.